ALNY:NGS-Alnylam Pharmaceuticals Inc. (USD)

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing

USD 237.46

Change

+3.65 (+1.56)%

Market Cap

USD 3.92B

Volume

0.87M

Analyst Target

USD 166.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Alnylam Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in developing novel therapeutics based on RNA interference, or RNAi. RNAi is a naturally occurring biological pathway within cells for regulating the expression of specific genes.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-07-31 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
REGN Regeneron Pharmaceuticals Inc

N/A

USD 130.01B
VRTX Vertex Pharmaceuticals Inc

N/A

USD 123.52B
ARGX argenx NV ADR

N/A

USD 32.41B
MRNA Moderna Inc

N/A

USD 28.23B
BGNE BeiGene Ltd

N/A

USD 20.54B
BMRN Biomarin Pharmaceutical Inc

N/A

USD 17.44B
RPRX Royalty Pharma Plc

N/A

USD 17.14B
UTHR United Therapeutics Corporatio..

N/A

USD 15.72B
INSM Insmed Inc

N/A

USD 12.93B
SRPT Sarepta Therapeutics Inc

N/A

USD 12.85B

ETFs Containing ALNY

GERM 10.74 % 0.00 %

N/A

N/A
GNOG:LSE Global X Genomics & Biote.. 6.95 % 0.00 %

N/A

USD 6.11M
MSGR 6.64 % 0.00 %

N/A

N/A
GNOM Global X Genomics & Biote.. 6.36 % 0.00 %

N/A

USD 0.09B
CURG:LSE VanEck Genomics and Healt.. 5.97 % 0.00 %

N/A

USD 6.97M
CURE:XETRA VanEck Genomics and Healt.. 5.76 % 0.00 %

N/A

N/A
GN0M:XETRA Global X Genomics & Biote.. 5.67 % 0.00 %

N/A

USD 7.05M
GNOM:SW Global X Genomics & Biote.. 5.67 % 0.00 %

N/A

USD 5.87M
BIOT:SW L&G Pharma Breakthrough U.. 3.89 % 0.00 %

N/A

N/A
BTEC:SW iShares Nasdaq US Biotech.. 3.20 % 0.00 %

N/A

N/A
ZUH:CA BMO Equal Weight US Healt.. 2.30 % 0.39 %

N/A

CAD 0.28B
EQJS:LSE Invesco NASDAQ Next Gener.. 2.26 % 0.00 %

N/A

USD 0.04B
JNDQ:AU BETAJNDQ ETF UNITS 2.14 % 0.00 %

N/A

N/A
EQQJ:SW Invesco NASDAQ Next Gener.. 2.11 % 0.00 %

N/A

N/A
EQQJ:XETRA Invesco NASDAQ Next Gener.. 2.08 % 0.00 %

N/A

USD 0.05B
TMFX Motley Fool Next Index ET.. 2.06 % 0.00 %

N/A

USD 0.02B
EQQJ:LSE Invesco NASDAQ Next Gener.. 2.02 % 0.00 %

N/A

N/A
LABU Direxion Daily S&P Biotec.. 1.96 % 1.14 %

N/A

USD 1.01B
WELP:LSE HAN-GINS Indxx Healthcare.. 1.36 % 0.00 %

N/A

N/A
W311:F HAN-GINS Indxx Healthcare.. 1.36 % 0.00 %

N/A

USD 0.02B
WELL:PA HAN-GINS Indxx Healthcare.. 1.36 % 0.00 %

N/A

N/A
WELL:SW HAN-GINS Indxx Healthcare.. 1.36 % 0.00 %

N/A

N/A
THNZ:XETRA L&G Global Thematic ESG E.. 0.87 % 0.00 %

N/A

N/A
IUSZ:SW iShares Edge MSCI USA Siz.. 0.47 % 0.00 %

N/A

N/A
IWSZ:SW iShares Edge MSCI World S.. 0.19 % 0.00 %

N/A

USD 0.26B
BBP Virtus LifeSci Biotech Pr.. 0.00 % 0.79 %

N/A

USD 0.02B
BIB ProShares Ultra Nasdaq Bi.. 0.00 % 0.95 %

N/A

USD 0.09B
FFTY Innovator IBD® 50 ETF 0.00 % 0.80 %

N/A

N/A
FXH First Trust Health Care A.. 0.00 % 0.63 %

N/A

USD 1.30B
IBB iShares Biotechnology ETF 0.00 % 0.47 %

N/A

USD 7.71B
LABS 0.00 % 0.45 %

N/A

N/A
QRH:CA 0.00 % 1.20 %

N/A

N/A
RBUS 0.00 % 0.30 %

N/A

N/A
BTEC:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

N/A

N/A
BTEK:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

N/A

N/A
BIGT:LSE L&G Pharma Breakthrough U.. 0.00 % 0.00 %

N/A

N/A
BTEE:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

N/A

N/A
XBI SPDR® S&P Biotech ETF 0.00 % 0.35 %

N/A

N/A
2B70:F iShares NASDAQ US Biotech.. 0.00 % 0.00 %

N/A

USD 0.52B
ETLI:F Legal & General UCITS ETF.. 0.00 % 0.00 %

N/A

N/A
2B70:XETRA iShares Nasdaq US Biotech.. 0.00 % 0.00 %

N/A

USD 0.52B
ETLI:XETRA L&G Pharma Breakthrough U.. 0.00 % 0.00 %

N/A

USD 0.02B
IS3T:XETRA iShares MSCI World Size F.. 0.00 % 0.00 %

N/A

USD 0.24B
QDVC:XETRA iShares Edge MSCI USA Siz.. 0.00 % 0.00 %

N/A

USD 0.19B
ZGEN:CA 0.00 % 0.00 %

N/A

N/A
W311:XETRA HAN-GINS Indxx Healthcare.. 0.00 % 0.00 %

N/A

USD 0.02B
BMED BlackRock Future Health E.. 0.00 % 0.00 %

N/A

USD 4.21M
QQQJ Invesco NASDAQ Next Gen 1.. 0.00 % 0.00 %

N/A

USD 0.65B
QQQN VictoryShares Nasdaq Next.. 0.00 % 0.00 %

N/A

USD 0.03B
IBBQ Invesco Nasdaq Biotechnol.. 0.00 % 0.00 %

N/A

USD 0.04B
XGES:LSE Xtrackers MSCI Genomic He.. 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 24.06% 74% C 83% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 24.06% 74% C 83% B
Trailing 12 Months  
Capital Gain 26.98% 74% C 81% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 26.98% 74% C 80% B-
Trailing 5 Years  
Capital Gain 220.98% 90% A- 92% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 220.98% 90% A- 92% A
Average Annual (5 Year Horizon)  
Capital Gain 15.31% 72% C 75% C
Dividend Return 15.31% 72% C 73% C
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 28.79% 86% B+ 62% D
Risk Adjusted Return 53.19% 94% A 81% B-
Market Capitalization 3.92B 99% N/A 97% N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A
Price/Book Ratio 142.92 1% 1%
Price / Cash Flow Ratio 283.95 1% 1%
Price/Free Cash Flow Ratio -81.96 99% 97%
Management Effectiveness  
Return on Equity -1,500.66% 4% 2%
Return on Invested Capital -34.83% 71% 27%
Return on Assets -3.05% 94% 44%
Debt to Equity Ratio -462.63% 98% 98%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.